BRAF and melanoma: In this study we analysed the ctDNA in BRAF and NRAS-mutated melanoma patients at baseline (n = 48) and within 8 weeks of treatment initiation (n = 25) to determine whether ctDNA correlates with treatment response and clinical benefit.